Our study provides novel insights for a comprehensive understanding of the anti-cancer effect of emodin in HCC, and suggests the miR-26a/TGF-β1/Akt signaling axis might be a promising approach to modulate the TME in HCC. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.